Online article for Non-subscribers

Pay per view

Heterocycles has a pay-per-view service for Non-subscribers.
You will be able to directly purchase the full text article through PayPal.
Your purchased Paper can be downloaded after the payment is completed.
An e-mail will be sent the URL to download the paper.
If you have any questions, please contact:

Price: ¥ 4,400 (Yen only)
Period: This Article can be accessed for 7 days.

Short Paper | Regular issue | Vol 100, No. 10, 2020, pp.1657-1665
Published online, 12th August, 2020
DOI: 10.3987/COM-20-14308
Some New C3- and Cs-Symmetrical Trialkylamino-substituted 1,3,5-Triazines and Their Biological Evaluation

Shunsuke Shimomura, Yusuke Inoue, Yuki Kawano, Yuka Fujita, Kanae Yamada, Yumemi Matsumoto, Kazumi Yokomizo, Jian-Rong Zhou, Kaori Ota, Nobuko Mibu, Makoto Furutachi, and Kunihiro Sumoto*

*Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan


We report the preparation of some new additionally synthesized symmetrical 1,3,5-triazines (TAZ) and the results of biological evaluation of their anti-herpes simplex virus type 1 (anti-HSV-1) activity and cytotoxic activity against Vero cells. All of the new trisubstituted TAZ derivatives 3a-3e showed considerable levels of anti-HSV-1 activity (EC50 = 4.4 ~ 30.3 μM). Among the tested compounds, two compounds (3c-2 and 3d) that have three 3,4-methylenedioxyphenylalkylamino groups showed low levels of cytotoxicity (CC50 > 200 μM) against Vero cells. On the other hand, the C3-symmetrical TAZ derivatives 3a-2, 3b-2 and 3e showed considerably high levels of cytotoxicity (CC50 = 8.91 ~ 15.2 μM). The structure-activity relationships for anti-HSV-1 activity and cytotoxicity of synthesized single-drug type 2,4,6-trisubstituted TAZ derivatives are also discussed.